Atossa Genetics (ATOS) Expected to Announce Earnings on Monday

Atossa Genetics (NASDAQ:ATOS) is projected to release its Q2 2025 earnings data before the market opens on Monday, August 11th. Analysts expect Atossa Genetics to post earnings of ($0.06) per share for the quarter.

Atossa Genetics (NASDAQ:ATOS) last announced its earnings results on Tuesday, May 13th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.01. On average, analysts expect Atossa Genetics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Atossa Genetics Trading Up 1.9%

Shares of ATOS opened at $0.79 on Friday. Atossa Genetics has a twelve month low of $0.55 and a twelve month high of $1.66. The company has a market cap of $101.66 million, a P/E ratio of -3.75 and a beta of 0.92. The company’s fifty day simple moving average is $0.85 and its 200-day simple moving average is $0.80.

Institutional Trading of Atossa Genetics

A hedge fund recently raised its stake in Atossa Genetics stock. Bank of America Corp DE increased its holdings in Atossa Genetics Inc. (NASDAQ:ATOS) by 51.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 111,475 shares of the company’s stock after acquiring an additional 37,809 shares during the quarter. Bank of America Corp DE owned approximately 0.09% of Atossa Genetics worth $105,000 as of its most recent SEC filing. 12.74% of the stock is owned by institutional investors.

Analysts Set New Price Targets

ATOS has been the topic of a number of research analyst reports. Craig Hallum upgraded shares of Atossa Genetics to a “strong-buy” rating and set a $4.00 price target on the stock in a report on Thursday, June 5th. Ascendiant Capital Markets upped their price target on shares of Atossa Genetics from $7.25 to $7.50 and gave the stock a “buy” rating in a report on Friday, June 6th.

About Atossa Genetics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.